长期阿片类药物剂量递减与过量或心理健康危机的关联
这项回顾性队列研究利用2008-2019年美国OptumLabs数据库,纳入113 618例稳定长期使用较高剂量(平均≥50 MME/d)阿片类药物的成人。暴露为7个月随访期内6个重叠60天窗口中任一窗口平均日剂量相对降低≥15%的递减事件。主要终点为随访至12个月内的药物过量或戒断急诊/住院就诊及心理健康危机(抑郁、焦虑、自杀未遂)就诊。结果显示递减期过量事件发生率为9.3/100人年(未递减期5.5/100人年,aIRR 1.68),心理健康危机为7.6/100人年(未递减期3.3/100人年,aIRR 2.28)。最大月度剂量递减速度每增加10%,过量aIRR 1.09,心理健康危机aIRR 1.18。
要点
- 长期稳定使用较高剂量(平均≥50 MME/d)阿片类药物的成人中,剂量递减与过量事件风险增加相关(aIRR 1.68, 95%CI 1.53-1.85)。
- 剂量递减同样与心理健康危机风险增加相关(aIRR 2.28, 95%CI 1.96-2.65)。
- 最大月度剂量递减速度每增加10%,过量风险aIRR 1.09(95%CI 1.07-1.11),心理健康危机aIRR 1.18(95%CI 1.14-1.21)。
- 递减期过量事件发生率为9.3/100人年,未递减期为5.5/100人年;心理健康危机分别为7.6/100人年与3.3/100人年。
- 该研究为观察性设计,结果不能证明因果关系,但提示对长期高剂量阿片类药物患者递减时需关注过量及心理健康风险。
适用人群与场景
- 美国成人,在12个月基线期内稳定使用较高剂量阿片类药物(平均≥50 MME/d),且有至少2个月随访。
- 排除标准原文未提及。
- 场景为门诊长期阿片类药物治疗患者,非急诊或ICU特定人群。
诊断标准与关键阈值
- 剂量递减定义:7个月随访期内6个重叠60天窗口中任一窗口平均日剂量相对降低≥15%。
- 最大月度剂量递减速度:同期计算。
- 主要结局:急诊或住院就诊的(1)药物过量或戒断,(2)心理健康危机(抑郁、焦虑、自杀未遂)。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性队列研究,使用2008-2019年OptumLabs数据仓库的去标识医疗和药房索赔数据。
- 样本量:最终队列113 618例患者(来自203 920个稳定基线期)。
- 人群:稳定长期使用较高剂量阿片类药物(平均≥50 MME/d)的成人,随访至少2个月。
- 暴露:剂量递减(7个月随访期内6个重叠60天窗口中任一窗口平均日剂量相对降低≥15%) vs 无递减。
- 主要终点:递减期过量事件调整发生率为9.3/100人年,未递减期为5.5/100人年(调整发生率差3.8/100人年,95%CI 3.0-4.6;aIRR 1.68,95%CI 1.53-1.85)。
- 次要终点:递减期心理健康危机调整发生率为7.6/100人年,未递减期为3.3/100人年(调整发生率差4.3/100人年,95%CI 3.2-5.3;aIRR 2.28,95%CI 1.96-2.65)。
- 剂量递减速度:最大月度剂量递减速度每增加10%,过量aIRR 1.09(95%CI 1.07-1.11),心理健康危机aIRR 1.18(95%CI 1.14-1.21)。
证据类型、等级与局限
- 证据类型:回顾性队列研究(观察性设计)。
- 局限:观察性研究设计,不能证明因果关系;原文指出解释受观察性设计限制。
对床旁实践的改变
- 对长期稳定使用较高剂量(平均≥50 MME/d)阿片类药物的患者进行剂量递减时,需警惕过量及心理健康危机风险增加。
- 递减速度较快可能与更高风险相关,临床决策时应权衡递减的潜在获益与风险。
- 该研究为观察性研究,不能确立因果关系,实践改变需结合个体化评估。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Opioid-related mortality and national prescribing guidelines have led to tapering of doses among patients prescribed long-term opioid therapy for chronic pain. There is limited information about risks related to tapering, including overdose and mental health crisis.
OBJECTIVE: To assess whether there are associations between opioid dose tapering and rates of overdose and mental health crisis among patients prescribed stable, long-term, higher-dose opioids.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using deidentified medical and pharmacy claims and enrollment data from the OptumLabs Data Warehouse from 2008 to 2019. Adults in the US prescribed stable higher doses (mean ≥50 morphine milligram equivalents/d) of opioids for a 12-month baseline period with at least 2 months of follow-up were eligible for inclusion.
EXPOSURES: Opioid tapering, defined as at least 15% relative reduction in mean daily dose during any of 6 overlapping 60-day windows within a 7-month follow-up period. Maximum monthly dose reduction velocity was computed during the same period.
MAIN OUTCOMES AND MEASURES: Emergency or hospital encounters for (1) drug overdose or withdrawal and (2) mental health crisis (depression, anxiety, suicide attempt) during up to 12 months of follow-up. Discrete time negative binomial regression models estimated adjusted incidence rate ratios (aIRRs) of outcomes as a function of tapering (vs no tapering) and dose reduction velocity.
RESULTS: The final cohort included 113 618 patients after 203 920 stable baseline periods. Among the patients who underwent dose tapering, 54.3% were women (vs 53.2% among those who did not undergo dose tapering), the mean age was 57.7 years (vs 58.3 years), and 38.8% were commercially insured (vs 41.9%). Posttapering patient periods were associated with an adjusted incidence rate of 9.3 overdose events per 100 person-years compared with 5.5 events per 100 person-years in nontapered periods (adjusted incidence rate difference, 3.8 per 100 person-years [95% CI, 3.0-4.6]; aIRR, 1.68 [95% CI, 1.53-1.85]). Tapering was associated with an adjusted incidence rate of 7.6 mental health crisis events per 100 person-years compared with 3.3 events per 100 person-years among nontapered periods (adjusted incidence rate difference, 4.3 per 100 person-years [95% CI, 3.2-5.3]; aIRR, 2.28 [95% CI, 1.96-2.65]). Increasing maximum monthly dose reduction velocity by 10% was associated with an aIRR of 1.09 for overdose (95% CI, 1.07-1.11) and of 1.18 for mental health crisis (95% CI, 1.14-1.21).
CONCLUSIONS AND RELEVANCE: Among patients prescribed stable, long-term, higher-dose opioid therapy, tapering events were significantly associated with increased risk of overdose and mental health crisis. Although these findings raise questions about potential harms of tapering, interpretation is limited by the observational study design.
参考来源
- Agnoli A, Xing G, Tancredi DJ, et al. Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids. JAMA. 2021. PMID: 34342618. doi:10.1001/jama.2021.11013
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。